Breaking News, Collaborations & Alliances

SynCrest Launches CRDMO Service for Peptide-based Therapeutics

To produce APIs, intermediates, and raw materials while addressing the specific challenges at each stage of the drug development.

SynCrest Inc., a peptide and nucleotide CRDMO (contract research, development and manufacturing organization) joint venture between Otsuka Chemical Co., Ltd., and Yokogawa Electric Corp., announced its services are now available for pharmaceutical companies and research institutions in Japan, Europe, North America, and South America. Using its advanced continuous flow synthesis with in-line measurement, the company can produce active pharmaceutical ingredients (APIs), intermediates, and raw m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters